Clover Biopharmaceuticals snaps up $230m Series C

Clover Biopharmaceuticals, a global clinical-stage biotechnology company, has secured $230 million in Series C financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this